Sage Therapeutics is a biopharmaceutical company focused on developing and commercializing medicines with the potential to transform the lives of people with debilitating disorders of the brain. Co.'s principal product, ZULRESSO, is a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. Co.'s other product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder, and PPD. Co. has a portfolio of other compounds that target GABAA receptors, including SAGE-324. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing.